In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AM­RN were blitzed Mon­day evening, los­ing bil­lions in val­ue as re­ports spread that the com­pa­ny had lost its high-pro­file ef­fort to keep its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.